A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
← catalyst calendarNCT07738614 · readout ≤ 134 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
56estimated
Sites
2
Countries
Singapore, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Eloralintide — also filed as LY3841136
- Drug: Placebo
- Drug: Acetaminophen
Primary outcomes
what the primary-completion date above is the date OFAcetaminophen Area Under the Concentration Versus Time Curve (AUC)
measured Baseline to Day 65
Acetaminophen Maximum Observed Concentration (Cₘₐₓ)
measured Baseline to Day 65
Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)
measured Baseline to Day 65
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed